Harpoon Therapeutics Inc

Harpoon Therapeutics — ESMO 2023

15 slides from Harpoon Therapeutics's conference presentation, Oct 23, 2023

  1. Slide 1: Spearheading Immunotherapies ESMO 2023 – HPN328 Investor Webcast

    Spearheading Immunotherapies ESMO 2023 – HPN328 Investor webcast october 23, 2023 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” "goal," “estimate” and similar expressions (as well as other words

  3. Slide 3: Harpoon Therapeutics: HPN328 Major Value Driver and Additional Opportunity

    Harpoon Therapeutics HPN328 Major Value Driver and Additional Opportunity in HPN217/601/Platform HPN217 (BCMA) – Clinically active and differentiated tolerability profile HPN601 (EpCAM) – IND ready conditionally activated T-cell engager with large market potential Multiple next-gen T-cell engager pl

  4. Slide 4: Large Addressable Population in SCLC and Other High Grade NENs with Significant Unmet Need

    Large Addressable Population in SCLC and Other High Grade NENs with Significant Unmet Need 7 Major Market Incidence1 5-yr Survival DLL3 Expression (>1%) Small Cell Lung Cancer ~90,000 7%2 82%3 Neuroendocrine Prostate Cancer (NEPC) ~20,0004 14%5,6 77%7 NET, High Grade ~11,500 mOS 10 months8 Highly ex

  5. Slide 5: HPN328 Phase 1 Interim Update

    Unaudited database as of 9/12/2023 Data subject to change HPN328 Phase 1 Interim Update

  6. Slide 6: HPN328: A DLL3-Targeted T Cell Engager

    Figure 1. HPN328 Mechanism of Action HPN328 Mechanism of Action T cell receptor complex DLL3 HPN328 Tumor Cell T cell Anti CD3 domain Anti albumin domain Anti DLL3 domain DLL3 is significantly expressed in SCLC and other neuroendocrine tumor types HPN328 is a DLL3-targeting T cell engager built on t

  7. Slide 7: HPN328 Phase 1 Trial Design

    HPN328 Phase 1 Trial YE 2022 Planned Targets: patients enrolled Optimization of priming dose for step-dosing regimens: 1 – 6 mg step-dose cohort opened Planned 2023 Events: Q1 2023: Start enrollment in atezolizumab combo cohorts Start enrollment in Q2W dosing cohorts for HPN328 monotherapy Mid-2023:

  8. Slide 8: Dose Escalation and Optimization Enrollment Nearing Completion

    Dose Escalation and Optimization Enrollment Nearing Completion Monotherapy Cohorts - Q4’23; Combination Cohorts - 1H’24 Unaudited database cutoff as of 9/12/2023, subject to change Dose Escalation 3+3 Design Including Fixed & Step Dose Cohorts and Dose Optimization (N=71) 0.015-3.6 mg N = 11 3.6à 7.

  9. Slide 9: Phase 1 Population Includes Heavily Pre-treated Refractory Patients

    Phase 1 Population Includes Heavily Pre-treated Refractory Patients Age (Years) Median 64 Range 41-81 Sex Female 29 (40.8%) Male 42 (59.2%) Race n (%) White 65 (91.5%) Asian 3 (4.2%) American Indian or Alaska Native 1 (1.4%) Multiple 1 (1.4%) Unknown 1 (1.4%) # Prior Therapies n (%) Median 2.5 Range

  10. Slide 10: Adverse Events Manageable with No DLTs at Target Doses

    Adverse Events Manageable with No DLTs at Target Doses No Grade 3 CRS with 1 mg Priming Regimens Unaudited database cutoff as of 9/12/2023, subject to change ICANS=Immune effector cell-associated neurotoxicity syndrome a Grading per CTCAE v5.0, except cytokine release syndrome (grading per ASTCT 201

  11. Slide 11: Response in 1 mg Priming Dose Optimization Cohorts

    SCLC NEN NEPC PD PD PD PD PD PD PD SD PD SD PR PR c PR PR PR c PR PR PR c CR c PD PR c PR c PR c CR CR* c PD SD PR PR PR 1-6 mg QW 1-12 mg QW 1-12 mg Q2W 1-12-24 mg QW 1-12-24 mg Q2W SD PR c c SD PD PR Axis capped at 100% although largest changes were >100.0% * Includes RECIST-based normalization of

  12. Slide 12: Prolonged Confirmed Responses Ongoing; Durability Data Maturing

    Prolonged Confirmed Responses Ongoing; Durability Data Maturing Time on Treatment: Patients Treated With 1 mg Priming Dose (N=47) Unaudited database cutoff as of 9/12/2023, subject to change Ongoing SCLC NEPC NEN Other Partial Response (PR) Confirmed PR Complete Response (CR) Confirmed CR c c c c c

  13. Slide 13: HPN328 Patient Case: Relapsed ES-SCLC Complete Response

    HPN328 Patient Case: Relapsed ES-SCLC Complete Response Patient History 61-year-old male Diagnosed in June 2021 with extensive-stage SCLC 60% cells positive for DLL3 Location of metastases TLs: lymph nodes x2 Non-TLs: Lymph nodes x4 Prior systemic treatment Cisplatin + Etoposide Carboplatin + Etopos

  14. Slide 14: HPN328 Patient Case: Relapsed Cervical Small Cell Carcinoma Response

    Pre-Treatment Wk 9 On Treatment Wk 27 On Treatment HPN328: started on 1mg prime and 6 mg target dose /week Well tolerated Complete Response at week 9, confirmed at week 13 RECIST v1.1: Target Lesion: CR 100% cells positive for DLL3 Ongoing response Remains on HPN328 treatment as of Sept 27, 2023 Pat

  15. Slide 15: HPN328 1mg Priming Dose Cohorts Clinically Active and Well Tolerated

    HPN328 - 1mg Priming Dose Cohorts Clinically Active and Well Tolerated in Ongoing Dose Escalation Study Active agent at 1mg priming dose cohorts at interim update 54% (19/35) overall response rate across all tumor types (SCLC, NEPC, other NENs) 32% (6/19) confirmed response rate in SCLC patients 5 o

Harpoon Therapeutics — ESMO 2023 on 6ix